Latest Breaking News On - Propionic acidemia - Page 1 : comparemela.com

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA ... 2024-04-03

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA .

Moderna, Inc. (NASDAQ:MRNA) Q4 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Moderna Fourth Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.

Year in Review: A look back at some of the top stories in 2023

Why Moderna (MRNA) Shares Are Trading Lower Today - Moderna (NASDAQ:MRNA)

William Blair initiated coverage on Moderna Inc (NASDAQ: MRNA) with a Market Perform rati

Moderna, Inc.: Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia , Presented at the 2023 ASGCT Annual Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early